Highlighting miRNA’s Increased Oncological Efficiency in Treating Chemotherapy-Resistant Cancers
- Exploiting multi-gene silencing by miRNA to disrupt cancer pathways, overcoming chemo-resistance in aggressive tumours
- Deploying tumour-homing vehicle free delivery for precise miRNA uptake, sparing healthy tissues and reducing toxicity
- Showing high safety and activity in Phase I clinical trials with miRNA-15a positioning it as a first-in-class oncology RNAi drug